Clinical Trial Update: A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension [Phase 2]

View source ↗

Summary

Boston Pharmaceuticals completed a Phase 2 study of BOS-580 in obese subjects at risk for or with biopsy-confirmed nonalcoholic steatohepatitis (NASH), includin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis
• Obesity

Drugs mentioned

• BOS-580

Snippet

Sponsor: Boston Pharmaceuticals | Conditions: Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED